产品介绍：
产品说明
一般描述
Ritonavir belongs to the group of protease inhibitors that are widely used in combination with other drugs in the prevention of HIV. Its mode of action involves binding to the active site of the protease enzyme and preventing the further maturation of new viral particles.
应用
Ritonavir may be used as a pharmaceutical primary standard for the quantification of the analyte in pharmaceutical formulations using chromatography techniques.
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
USP issued SDS can be found here.
Sales restrictions may apply.
基本信息
| 经验(实验)分子式 | C37H48N6O5S2 |
| 分子量 | 720.94 |
| NACRES | NA.24 |
产品性质
| 生物来源 | synthetic |
| 等级 | pharmaceutical primary standard |
| agency | USP |
| 蒸汽压 | <0.0000001 kPa ( 25 ℃) |
| 形式 | powder |
| 包装 | pkg of 200 mg |
| manufacturer/tradename | USP |
| 储存条件 | protect from light |
| 颜色 | white to tan |
| 溶解性 | acetonitrile: slightly soluble ethanol: freely soluble methanol: freely soluble methylene chloride: freely soluble water: practically insoluble |
| application(s) | pharmaceutical (small molecule) |
| 格式 | neat |
| InChI | 1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1 |
| InChI key | NCDNCNXCDXHOMX-XGKFQTDJSA-N |
安全信息
| 象形图 |  |
| 警示用语： | Warning |
| 危险声明 | H302 + H312 + H332 |
| 预防措施声明 | P261 - P280 - P301 + P312 + P330 |
| 危险分类 | Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral |
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
